ACHA to Recognize Evan Michael Zahn, MD, for Contributions to Congenital Interventional Cardiology
The Adult Congenital Heart Association (ACHA) has announced Evan Michael Zahn, MD, professor of Pediatrics and Director of the Guerin Family Congenital Heart Program in the Smidt Heart Institute at Cedars-Sinai, as its honoree for the organization’s Los Angeles Benefit on November 2. Dr. Zahn will be honored for his contributions to the field of adult congenital cardiology during a fundraiser from 1 p.m. to 4 p.m. at the Propagator, part of Firestone Walker Brewing Company, in Marina Del Rey, CA.
“Dr. Zahn has played and continues to play a key role in the field of congenital interventional cardiology. He was one the early leaders in transcatheter pulmonary valve interventions and has been instrumental in clinical trials that resulted in FDA approval for new devices used for treatments,” said Jamil Aboulhosn, MD, director of the Ahmanson/UCLA Adult Congenital Heart Disease (ACHD) Center and ACHA Medical Advisory Board chair. “Dr. Zahn is considered a global leader in the field and his creativity, humble nature, and fantastic sense of humor are widely appreciated by his patients and colleagues. His work has positively impacted the ACHD community; ACHA would like to show its appreciation through this well-deserved award.”
A distinguished researcher, Dr. Zahn has participated as both a site and national primary investigator in numerous clinical trials, which have led to revolutionizing the treatment options for ACHD patients, often sparing many from open heart surgery. Other areas of focused exploration over his career have included early post-operative intervention, development of hybrid procedures, and the utility and feasibility of stents in small babies.
“Evan is the rare combination of consummate clinician, researcher and out-of-the-box thinker,” said Eduardo Marbán, MD, PhD, director of the Smidt Heart Institute at Cedars-Sinai. “His entire career has focused on treating congenital heart disease using smaller, faster, better and safer approaches—to the good of his patients, and that of humankind.”
ACHA is thrilled to honor Dr. Zahn for his devoted work to medical advances for all people born with heart defects, as the organization continues to increase its support to CHD patients and medical professionals in the entire Southern California region.
“Through ACHA’s tireless advocacy and outreach both among patients and within the medical community, they have helped the field of ACHD to obtain much-needed recognition as a cardiac subspecialty deserving of its own formal training, accreditation, and research to promote continued improvement in the care and outcomes of our ACHD patients,” said Rose Tompkins, MD, associate director of the Adult Congenital Heart Program in the Smidt Heart Institute. “Cedars-Sinai has a strong tradition in supporting the health of our community, and we are very honored that Dr. Zahn's groundbreaking work has been recognized and honored by such a prominent organization at the forefront of congenital heart care.”
To purchase tickets for the Los Angeles Benefit, click here.